$NVRO
NEVRO CORP

2014 Q4 Form 10-Q Financial Statement

#000119312514431145 Filed on December 02, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $9.715M $8.668M $6.198M
YoY Change 56.79% 39.85%
Cost Of Revenue $3.000M $2.737M $2.470M
YoY Change 15.38% 10.81%
Gross Profit $6.695M $5.931M $3.728M
YoY Change 83.73% 59.09%
Gross Profit Margin 68.91% 68.42% 60.15%
Selling, General & Admin $9.100M $7.193M $4.504M
YoY Change 65.45% 59.7%
% of Gross Profit 135.92% 121.28% 120.82%
Research & Development $4.700M $5.236M $4.586M
YoY Change 2.17% 14.17%
% of Gross Profit 70.2% 88.28% 123.02%
Depreciation & Amortization $30.00K $26.00K $10.00K
YoY Change 50.0% 160.0%
% of Gross Profit 0.45% 0.44% 0.27%
Operating Expenses $13.80M $12.43M $9.090M
YoY Change 36.63% 36.73%
Operating Profit -$7.106M -$6.498M -$5.362M
YoY Change 8.74% 21.19%
Interest Expense -$100.0K $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net -$1.000M -$1.270M $436.0K
YoY Change 400.0% -391.28%
Pretax Income -$8.200M -$7.748M -$4.885M
YoY Change 22.39% 58.61%
Income Tax $100.0K $137.0K $131.0K
% Of Pretax Income
Net Earnings -$8.310M -$7.885M -$5.016M
YoY Change 23.29% 57.2%
Net Earnings / Revenue -85.54% -90.97% -80.93%
Basic Earnings Per Share
Diluted Earnings Per Share -$333.3K -$318.5K -$219.3K
COMMON SHARES
Basic Shares Outstanding 24.84M shares 1.372M shares 1.093M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $176.8M $33.69M
YoY Change 212.76%
Cash & Equivalents $25.29M $14.48M $10.97M
Short-Term Investments $151.5M $19.22M
Other Short-Term Assets $2.900M $2.000M
YoY Change 93.33%
Inventory $14.86M $12.12M
Prepaid Expenses
Receivables $6.610M $5.676M
Other Receivables $0.00 $0.00
Total Short-Term Assets $201.1M $53.48M
YoY Change 168.98%
LONG-TERM ASSETS
Property, Plant & Equipment $647.0K $289.0K
YoY Change 452.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $424.0K $2.045M
YoY Change 92.73%
Total Long-Term Assets $1.371M $2.634M
YoY Change 115.23%
TOTAL ASSETS
Total Short-Term Assets $201.1M $53.48M
Total Long-Term Assets $1.371M $2.634M
Total Assets $202.5M $56.11M
YoY Change 168.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.460M $3.496M
YoY Change 40.38%
Accrued Expenses $6.268M $5.116M
YoY Change 38.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.80M $8.689M
YoY Change 36.61%
LONG-TERM LIABILITIES
Long-Term Debt $19.50M $0.00
YoY Change
Other Long-Term Liabilities $117.0K $67.00K
YoY Change 88.71%
Total Long-Term Liabilities $117.0K $67.00K
YoY Change 88.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.80M $8.689M
Total Long-Term Liabilities $117.0K $67.00K
Total Liabilities $30.43M $8.756M
YoY Change 281.95%
SHAREHOLDERS EQUITY
Retained Earnings -$122.0M -$113.7M
YoY Change 33.82%
Common Stock $294.0M $7.662M
YoY Change 5413.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $172.1M -$106.0M
YoY Change
Total Liabilities & Shareholders Equity $202.5M $56.11M
YoY Change 168.52%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$8.310M -$7.885M -$5.016M
YoY Change 23.29% 57.2%
Depreciation, Depletion And Amortization $30.00K $26.00K $10.00K
YoY Change 50.0% 160.0%
Cash From Operating Activities -$9.150M -$6.920M -$4.160M
YoY Change 88.27% 66.35%
INVESTING ACTIVITIES
Capital Expenditures -$390.0K -$60.00K $0.00
YoY Change 550.0%
Acquisitions
YoY Change
Other Investing Activities -$132.0M $4.880M $4.420M
YoY Change -2202.23% 10.41%
Cash From Investing Activities -$132.4M $4.830M $4.420M
YoY Change -2228.94% 9.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 152.4M -830.0K 10.00K
YoY Change 190362.5% -8400.0%
NET CHANGE
Cash From Operating Activities -9.150M -6.920M -4.160M
Cash From Investing Activities -132.4M 4.830M 4.420M
Cash From Financing Activities 152.4M -830.0K 10.00K
Net Change In Cash 10.80M -2.920M 270.0K
YoY Change 650.0% -1181.48%
FREE CASH FLOW
Cash From Operating Activities -$9.150M -$6.920M -$4.160M
Capital Expenditures -$390.0K -$60.00K $0.00
Free Cash Flow -$8.760M -$6.860M -$4.160M
YoY Change 82.5% 64.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24844657 shares
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10968000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1582292 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1582292 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
472000000 shares
CY2014Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
364993831 shares
CY2014Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
15208048 shares
CY2014Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17769875 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
153366000
CY2014Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
77000
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
304000
CY2014Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
154110000
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8689000
CY2014Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
978000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
2000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-21000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3496000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113650000
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
7660000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5116000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
-106009000
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
67000
CY2014Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
449000
CY2014Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56113000
CY2014Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
364000
CY2014Q3 us-gaap Liabilities
Liabilities
8756000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2946000
CY2014Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
103000
CY2014Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14476000
CY2014Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
4800000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
289000
CY2014Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
26108000
CY2014Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
21265000
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1987000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
300000
CY2014Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
5300000
CY2014Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6896000
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
593000
CY2014Q3 us-gaap Assets
Assets
56113000
CY2014Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
19216000
CY2014Q3 us-gaap Inventory Net
InventoryNet
12124000
CY2014Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5228000
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5676000
CY2014Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2045000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
53479000
CY2014Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
21267000
CY2014Q3 nvro Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
379000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5618000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1120416 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1120416 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
472000000 shares
CY2013Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
364993831 shares
CY2013Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
15208048 shares
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17956415 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
153235000
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
191000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
239000
CY2013Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
154110000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7904000
CY2013Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
929000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3177000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-91150000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5331000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4536000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-85790000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
62000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
422000
CY2013Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75411000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
186000
CY2013Q4 us-gaap Liabilities
Liabilities
7966000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2545000
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
182000
CY2013Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
17000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12409000
CY2013Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2400000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
117000
CY2013Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
47995000
CY2013Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
45610000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1514000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
300000
CY2013Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
5700000
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5528000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
356000
CY2013Q4 us-gaap Assets
Assets
75411000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
44123000
CY2013Q4 us-gaap Inventory Net
InventoryNet
10123000
CY2013Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4595000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6605000
CY2013Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
220000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
74774000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
45623000
CY2013Q4 nvro Accrued Clinical And Research Expenses Current
AccruedClinicalAndResearchExpensesCurrent
454000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16239000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
837742 shares
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
247049 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-23.14
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17797596 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1084791 shares
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
59194000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
200000
us-gaap Gross Profit
GrossProfit
10383000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-421000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
36000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
33273000
nvro Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
346000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-695000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1495000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18995000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18616000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-407000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19350000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-491000
us-gaap Revenues
Revenues
17304000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19386000
us-gaap Net Income Loss
NetIncomeLoss
-19274000
us-gaap Investment Income Interest
InvestmentIncomeInterest
112000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
607000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
36000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1117000
us-gaap Operating Expenses
OperatingExpenses
28999000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15707000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13292000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
193000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5350000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
279000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
112000
us-gaap Cost Of Revenue
CostOfRevenue
6921000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
28000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
47710000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
36000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1075000
us-gaap Inventory Write Down
InventoryWriteDown
1004000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-26121000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
47674000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
390000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
604000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holder of each share of common stock was entitled to one vote
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
NEVRO CORP
dei Trading Symbol
TradingSymbol
NVRO
us-gaap Other Information Pertaining To Income Taxes
OtherInformationPertainingToIncomeTaxes
The Company records uncertain tax positions on the basis of a two-step process whereby (1) a determination is made as to whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the related tax authority.
us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
Each share of convertible preferred stock was convertible into shares of common stock at the option of the holder at any time.
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
Each share of convertible preferred stock was convertible into shares of common stock at the option of the holder at any time. Conversion is automatic upon either the written consent of not less than the majority of the holders of the convertible preferred stock outstanding or the effective date of a firm commitment underwritten public offering that yields net proceeds to the Company of not less than $50,000,000. Each share of convertible preferred stock would have been converted into the number of shares of common stock which results from dividing the original issue price for such series convertible preferred stock by the conversion price for such series that is in effect at the time of conversion. The per share conversion price of Series A preferred stock, Series B and Series C preferred stock was $8.74, $10.75 and $11.11, respectively. Each share of preferred stock was automatically convertible into common stock at the conversion ratio of 1-to-1.
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-22000000
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-24 reverse stock split
us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
Limited one-year warranty
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant accounting estimates and management judgments reflected in the condensed consolidated financial statements include items such as allowances for doubtful accounts; clinical accruals; stock-based compensation; depreciation and amortization periods; inventory valuation; valuation of investments and deferred tax assets, including valuation allowances. Estimates are based on historical experience, where applicable, and other assumptions believed to be reasonable by the management. Actual results may differ from those estimates under different assumptions or conditions.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1181511 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Business
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
455000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
319000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
45361000
us-gaap Dividends Common Stock
DividendsCommonStock
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
50928 shares
dei Entity Central Index Key
EntityCentralIndexKey
0001444380
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-19.04
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17769875 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Concentration of Credit Risk and Other Risks and Uncertainties</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and investments. The majority of the Company&#x2019;s cash is held by one financial institution in the United States of America in excess of federally insured limits. The Company maintained investments in money market funds that were not federally insured during the periods ended September&#xA0;30, 2014 and December&#xA0;31, 2013 and held cash in foreign banks of approximately $5.3 million at September&#xA0;30, 2014 and $5.7&#xA0;million at December&#xA0;31, 2013 that was not federally insured. The Company has not experienced any losses on its deposits of cash and cash equivalents.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> All of the Company&#x2019;s revenue has been derived from sales of its products in international markets, principally Australia and Europe. In the international markets in which the Company participates, the Company uses both a direct sales force and distributors to sell its products. The Company performs ongoing credit evaluation of its direct customers and distributors, does not require collateral, and maintains allowances for potential credit losses on customer accounts when deemed necessary.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> During the three and nine month periods ended September&#xA0;30, 2014 and 2013, no customers accounted for more than 10% of the Company&#x2019;s revenue. As of September&#xA0;30, 2014, one customer accounted for 11% of the accounts receivable balance. As of December&#xA0;31, 2013, one customer accounted for 11% of the Company&#x2019;s accounts receivable balance.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is subject to risks common to early-stage medical device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, uncertainty of market acceptance of products, and the need to obtain additional financing. The Company is dependent on third party manufacturers and suppliers, in some cases sole- or single-source suppliers.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"> &#xA0;</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"> There can be no assurance that the Company&#x2019;s products or services will continue to be accepted in the marketplace, nor can there be any assurance that any future products or services can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that such products or services will be successfully marketed, if at all.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company&#x2019;s products require approval from the U.S. Food and Drug Administration prior to commencing commercial sales in the U.S. There can be no assurance that the Company&#x2019;s products will receive all of the required approvals. If the Company is denied such approvals or such approvals are delayed, it may have a material adverse impact on the Company&#x2019;s results of operations, financial position and liquidity.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to launch and commercialize any products or product candidates for which it receives regulatory approval. There can be no assurance that such financing will be available or will be at terms acceptable by the Company.</p> </div>
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1232439 shares
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
20767000
us-gaap Gross Profit
GrossProfit
14601000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-263000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-49000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-775000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1825000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2458000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21995000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
0
us-gaap Operating Income Loss
OperatingIncomeLoss
-21200000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-836000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22549000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-888000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-40000
us-gaap Revenues
Revenues
22858000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
236000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22500000
us-gaap Net Income Loss
NetIncomeLoss
-22369000
us-gaap Investment Income Interest
InvestmentIncomeInterest
93000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-929000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1234000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Operating Expenses
OperatingExpenses
35801000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15082000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20719000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
5000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2067000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
374000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
131000
us-gaap Cost Of Revenue
CostOfRevenue
8257000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
65000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-291000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
955000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
605000
us-gaap Inventory Write Down
InventoryWriteDown
457000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
24358000
nvro Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
128000
nvro Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
1246000
nvro Unpaid Deferred Offering Costs
UnpaidDeferredOfferingCosts
532000
nvro Initial Public Offerings Completion Date
InitialPublicOfferingsCompletionDate
2014-11-12
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21100000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-26000000
CY2013Q1 us-gaap Sale Of Stock Percentage Of Ownership Before Transaction
SaleOfStockPercentageOfOwnershipBeforeTransaction
0.10 pure
CY2013Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
650848 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
912838 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
180347 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.54
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1093185 shares
CY2013Q3 us-gaap Gross Profit
GrossProfit
3728000
CY2013Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
22000
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4885000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5362000
CY2013Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
450000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5035000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
436000
CY2013Q3 us-gaap Revenues
Revenues
6198000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5057000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-5016000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
41000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
423000
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
9090000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4586000
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4504000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
131000
CY2013Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
41000
CY2013Q3 us-gaap Cost Of Revenue
CostOfRevenue
2470000
CY2013Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9000
CY2013Q3 us-gaap Inventory Write Down
InventoryWriteDown
200000
CY2013Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
126000
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1329610 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
42601 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.96
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1372211 shares
CY2014Q3 us-gaap Gross Profit
GrossProfit
5931000
CY2014Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-38000
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7748000
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6498000
CY2014Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1259000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7967000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1270000
CY2014Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000
CY2014Q3 us-gaap Revenues
Revenues
8668000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7929000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-7885000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
20000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
436000
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
12429000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5236000
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7193000
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
137000
CY2014Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
44000
CY2014Q3 us-gaap Cost Of Revenue
CostOfRevenue
2737000
CY2014Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
26000
CY2014Q3 us-gaap Inventory Write Down
InventoryWriteDown
200000
CY2014Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
173000

Files In Submission

Name View Source Status
0001193125-14-431145-index-headers.html Edgar Link pending
0001193125-14-431145-index.html Edgar Link pending
0001193125-14-431145.txt Edgar Link pending
0001193125-14-431145-xbrl.zip Edgar Link pending
d812396d10q.htm Edgar Link pending
d812396dex311.htm Edgar Link pending
d812396dex312.htm Edgar Link pending
d812396dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
nvro-20140930.xml Edgar Link completed
nvro-20140930.xsd Edgar Link pending
nvro-20140930_cal.xml Edgar Link unprocessable
nvro-20140930_def.xml Edgar Link unprocessable
nvro-20140930_lab.xml Edgar Link unprocessable
nvro-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending